1. Home
  2. LENZ vs EQ Comparison

LENZ vs EQ Comparison

Compare LENZ & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LENZ Therapeutics Inc.

LENZ

LENZ Therapeutics Inc.

HOLD

Current Price

$3.22

Market Cap

106.8M

Sector

Health Care

ML Signal

HOLD

Logo Equillium Inc.

EQ

Equillium Inc.

HOLD

Current Price

$1.26

Market Cap

89.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LENZ
EQ
Founded
2019
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
106.8M
89.4M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
LENZ
EQ
Price
$3.22
$1.26
Analyst Decision
Buy
Strong Buy
Analyst Count
7
9
Target Price
★ $23.86
$8.56
AVG Volume (30 Days)
★ 744.4K
441.5K
Earning Date
11-04-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
$19,088,000.00
★ $41,095,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$152.18
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.12
$1.16
52 Week High
$32.92
$6.20

Technical Indicators

Market Signals
Indicator
LENZ
EQ
Relative Strength Index (RSI) 32.50 34.91
Support Level N/A N/A
Resistance Level $6.11 $1.51
Average True Range (ATR) 0.21 0.13
MACD 0.00 0.02
Stochastic Oscillator 13.89 23.20

Price Performance

Historical Comparison
LENZ
EQ

About LENZ LENZ Therapeutics Inc.

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.

About EQ Equillium Inc.

Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.

Share on Social Networks: